<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860037</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0229</org_study_id>
    <nct_id>NCT04860037</nct_id>
  </id_info>
  <brief_title>Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients</brief_title>
  <official_title>Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients : What About Their Consequences ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnosis and the follow-up of acromegalic patients are based on the mesurement of Growth&#xD;
      hormone (GH) and IGF1 rates. However, the literature described some cases of patient for whom&#xD;
      the investigators observed a discrepancy between GH and IGF1 rates. Since the acromegaly is a&#xD;
      rare disease and this phenomenon concerns about 30% of these patients, there is a lack of&#xD;
      investigations about consequences that this discordance may induces. In this study, the&#xD;
      investigators aimed at assessing if patients with discordance between GH and IGF1 rates&#xD;
      present a different risk of recurrence and complications related to acromegaly, from patients&#xD;
      with concordant results.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2010</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of complications and/or recidivism related to acromegaly</measure>
    <time_frame>day 1</time_frame>
    <description>The investigators check in the patient file if there is complications or pathology recidivism detected at the last full check-up of the disease, assessed by blood-control and complementary exams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease's specificity</measure>
    <time_frame>day 1</time_frame>
    <description>The investigators collected datas about disease's diagnosis (IRM characteristic, GH/IGF1 rates, clinical presentation) to evaluate if there is a different initial presentation between groups.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Acromegaly</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult acromegalic patient followed up in the Occitanie region (independent endocrinologist&#xD;
        ou working in hospital of Montpellier, Nimes or Béziers)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Acromegaly followed up in one of the center (Montpellier, Nimes or Béziers hospital,&#xD;
             independent endocrinologist) between 2010 and 2021&#xD;
&#xD;
          -  Age over 18 years old&#xD;
&#xD;
          -  Measurement of GH and IGF1 rates at the last visit control available&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Lost to follow-up&#xD;
&#xD;
          -  Status about complications related to acromegaly unknown&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle RAINGEARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucile MARTY, intern</last_name>
    <phone>06.71.31.76.37</phone>
    <phone_ext>33</phone_ext>
    <email>lucile-marty@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucile MARTY, intern</last_name>
      <phone>06.71.31.76.37</phone>
      <phone_ext>33</phone_ext>
      <email>lucile-marty@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endocrinology</keyword>
  <keyword>Acromegaly</keyword>
  <keyword>Discrepancy</keyword>
  <keyword>Complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

